콘텐츠로 건너뛰기
Merck
  • Biomarker identification with ligand-targeted nucleoprotein assemblies.

Biomarker identification with ligand-targeted nucleoprotein assemblies.

Nanomedicine (London, England) (2011-07-02)
Elizabeth M Singer, Laura E Crocitto, Yuri Choi, Sofia Loera, Lawrence M Weiss, S Ashraf Imam, Timothy G Wilson, Steven S Smith
초록

Since many biomarkers of both the tumor and its microenvironment are expected to involve differential expression of divalent proteins capable of protein or peptide ligand interaction, we are developing multivalent nanodevices for the identification of biomarkers in prostate cancer. We compared a multivalent thioredoxin-targeted nanodevice with monovalent thioredoxin in binding to human prostate cell line(s) and freshly frozen tissue specimens obtained after resection from patients with biopsy-proven prostate cancer. The nanodevice binds specifically with enhanced avidity to tumor microenvironment-associated stromal cells in prostate cancer tissue specimens. Cells that bind the nanodevice also reacted with antibodies to dimeric thioredoxin reductases 1 and 2, suggesting the utility of the nanodevice as a potentially specific and functional marker of tumor stromal cells.